Jill Wechsler

Jill Wechsler is the Washington Editor for Pharmaceutical Executive and writes about federal government policies and programs that affect the pharmaceutical industry. Her monthly Washington Report discusses legislative proposals, FDA initiatives and actions by other government agencies, including Medicare pharmacy benefit proposals, federal investigations related to pharmaceutical company marketing, debate over DTC advertising, generic drug competition, over-the-counter initiatives, among other topics. She has written for PE for more than ten years and also covers Washington for other Advanstar publications, including Pharmaceutical Technology, Applied Clinical Trials, BioPharm, Managed Healthcare Executive and Formulary. Prior to that she reported on government policies and a wide range of topics for business and consumer publications.

Opioid abuse generates calls for efforts to curb distribution, develop abuse-resistant formulations.

Legal battles and regulatory missteps undermine access to low-cost generics, at home and abroad.

There seems no end to demands for data on clinical research, conflicts of interest, company payments, and drug prices.

Pressure for action on key enforcement and regulatory issues may prompt congressional action this year.

More new medicines gained market approval in 2012, but marketers face resistance from payers looking to cut healthcare spending, writes Jill Wechsler.

FDA policies will reshape drug development, while pressure to cut healthcare spending may alter drug coverage and pricing.

Tax and budget decisions will shape the healthcare market and drug research and regulation.

While the nation was embroiled in the presidential elections, a number of important legal and regulatory issues absorbed pharmaceutical executives, writes Jill Wechsler.

New user fee programs precipitate major changes at an agency under constant and intense scrutiny, writes Jill Wechsler.